A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 (fremanezumab) is safe and provides migraine prevention in subjects with high frequency episodic migraine.
Epistemonikos ID: 9de687676ad179da6a5fdb29797624f9ccd19123
First added on: May 11, 2024